Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MRE11 meiotic recombination 11 homolog A (S. cerevisiae)

Written2004-05Nancy Uhrhammer
Centre Jean-Perrin, BP 392, 63000 Clermont-Ferrand, France

(Note : for Links provided by Atlas : click)

Identity

Alias_namesMRE11A
MRE11 meiotic recombination 11 homolog A (S. cerevisiae)
MRE11 homolog A, double strand break repair nuclease
Alias_symbol (synonym)ATLD
HGNC (Hugo) MRE11
LocusID (NCBI) 4361
Atlas_Id 247
Location 11q21  [Link to chromosome band 11q21]
Location_base_pair Starts at 94150471 and ends at 94227074 bp from pter ( according to hg19-Feb_2009)
Fusion genes
(updated 2016)
MRE11A (11q21) / YAP1 (11q22.1)MRE11A (11q21) / ZNF385A (12q13.13)
Note Pseudogenes have been localized to chromosomes 3q25 and 7q11.2-q11.3.

DNA/RNA

Description 22 exons spanning 76 kb
Transcription Two isoforms are expressed, isoform 1 at 4772nt; isoform 2, 4688 nt, transcribed from an alternative first (noncoding) exon and lacking exon 5.

Protein

Description Both isoforms are approximately 80 kDa. Isoform 1 includes 708 amino acids; isoform 2 includes 680. Molecular studies of Mre11 typically do not distinguish between the different isoforms. Mre11 is a subunit of the Rad50/Mre11/NBS1 (R/M/N) complex and serves as a single-strand DNA endonuclease, a 3' to 5' DNA exonuclease, and to open hairpin DNA structures.
Expression All tissues examined, with higher levels in proliferating tissues.
Localisation Nuclear.
Function Mre11 participates in the repair of DNA double-strand breaks and replication errors as well as in meiotic homologous recombination. The R/M/N complex is part of the BRCA1-associated genome surveillance complex (BASC). The phosphorylation of Mre11 and NBS1 by another member of this super-complex, ATM, is essential for an early step in the response to DNA double-strand breaks (DSBs) and for their repair by either non-homologous end joining (NHEJ) or homologous recombination (HR). The interaction of DNA end-bound Mre11 with Ku70 may direct the break to rejoining by NHEJ, while the absense of Ku70 favors repair by HR. Current models propose DSB detection by R/M/N is required for the activation of ATM, which in turn phosphorylates Mre11 and NBS1, thus placing Mre11 both upstream and downstream of ATM in the DNA damage response signal transduction cascade.

A mechanism has been proposed in which each end of a DNA DSB is bound by an R/M/N dimer, the two dimers being held to each other via the Zinc-hook domain of each Rad50 unit. As the Zinc-hook of Rad50 is located at the end of a long coiled-coil domain, this provides a flexible structure in which each DNA end is accessible to additional repair enzymes while being held in close proximity to each other in preparation for re-ligation.

Cells lacking Mre11 are deficient in DSB repair, and exhibit hypersensitivity to DNA damaging agents such as ionizing radiation and radiomimetic drugs. Such cells also have abnormal DNA replication and high levels of chromosomal instability.

Homology The gene is conserved throughout eukaryotes, with 70% nucleic acid homology to S. cerevisiea Mre11.

Mutations

Germinal The hypomorphic arg633ter, asn117ser and arg571ter alleles have been described in ATLD patients. Homozygosity for null alleles is thought to be lethal in embryogenesis, as is the case in Mre11 knockout mice. Germline mutations have also been found in sporadic hematopoetic malignancies, with loss of the wild-type allele in the malignant cells.
Somatic Rare mutations have been found in breast cancer and lymphoma. In colon cancers not expressing Mre11, the mutation of a poly-T tract in intron 4 has been shown to induce a splicing error that truncates the protein. Seven of 20 gastric tumors failed to express Mre11, although the cause of this was not demonstrated.

Implicated in

Note
Entity Ataxia telangiectasia - like disorder (ATLD)
Disease Ataxia telangiectasia-like disorder is a progressive cerebellar degenerative disease with telangiectasia, immunodeficiency, cancer risk, radiosensitivity, and chromosomal instability. Only a very few ATLD patients are known, in spite of the suggestion that as many as 6% of "A-T" patients may in fact have mutations in Mre11 (this figure is calculated be comparing the size (and thus the opportunity for mutation) of the two genes, as well as the observation that a small minority of A-T patients express apparently normal ATM and for whom no ATM mutation has been detected). The two disorders cannot be distinguished by their phenotypes, though there is some indication that ATLD may have a milder course. The severity of the disease may be dependent on the residual activity of the mutated Mre11 alleles.
Prognosis Poor, though the course of the disease may be milder than found in classic A-T.
Cytogenetics Spontaneous chromatid/chromosome breaks; non clonal stable chromosome rearrangements involving immunoglobulin superfamily genes e.g. inv(7)(p14q35); clonal rearrangements.
  

Bibliography

Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication.
Costanzo V, Robertson K, Bibikova M, Kim E, Grieco D, Gottesman M, Carroll D, Gautier J
Molecular cell. 2001 ; 8 (1) : 137-147.
PMID 11511367
 
The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways.
Falck J, Petrini JH, Williams BR, Lukas J, Bartek J
Nature genetics. 2002 ; 30 (3) : 290-294.
PMID 11850621
 
Alterations of the double-strand break repair gene MRE11 in cancer.
Fukuda T, Sumiyoshi T, Takahashi M, Kataoka T, Asahara T, Inui H, Watatani M, Yasutomi M, Kamada N, Miyagawa K
Cancer research. 2001 ; 61 (1) : 23-26.
PMID 11196167
 
Human MRE11 is inactivated in mismatch repair-deficient cancers.
Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, Ottini L, Crescenzi M, Martinotti S, Bignami M, Frati L, Screpanti I, Gulino A
EMBO reports. 2002 ; 3 (3) : 248-254.
PMID 11850399
 
The Rad50 zinc-hook is a structure joining Mre11 complexes in DNA recombination and repair.
Hopfner KP, Craig L, Moncalian G, Zinkel RA, Usui T, Owen BA, Karcher A, Henderson B, Bodmer JL, McMurray CT, Carney JP, Petrini JH, Tainer JA
Nature. 2002 ; 418 (6897) : 562-566.
PMID 12152085
 
Isolation and characterization of the human MRE11 homologue.
Petrini JH, Walsh ME, DiMare C, Chen XN, Korenberg JR, Weaver DT
Genomics. 1995 ; 29 (1) : 80-86.
PMID 8530104
 
The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder.
Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH, Taylor AM
Cell. 1999 ; 99 (6) : 577-587.
PMID 10612394
 
BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.
Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J
Genes & development. 2000 ; 14 (8) : 927-939.
PMID 10783165
 

Citation

This paper should be referenced as such :
Uhrhammer, N. MRE11A (MRE11 meiotic recombination 11 homolog A (S
cerevisiae))
Atlas Genet Cytogenet Oncol Haematol. 2004;8(3):198-199.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/MRE11ID247.html


External links

Nomenclature
HGNC (Hugo)MRE11   7230
LRG (Locus Reference Genomic)LRG_85
Cards
AtlasMRE11ID247.txt
Entrez_Gene (NCBI)MRE11  4361  MRE11 homolog, double strand break repair nuclease
AliasesATLD; HNGS1; MRE11A; MRE11B
GeneCards (Weizmann)MRE11
Ensembl hg19 (Hinxton)ENSG00000020922 [Gene_View]  chr11:94150471-94227074 [Contig_View]  MRE11 [Vega]
Ensembl hg38 (Hinxton)ENSG00000020922 [Gene_View]  chr11:94150471-94227074 [Contig_View]  MRE11 [Vega]
ICGC DataPortalENSG00000020922
TCGA cBioPortalMRE11
AceView (NCBI)MRE11
Genatlas (Paris)MRE11
WikiGenes4361
SOURCE (Princeton)MRE11
Genetics Home Reference (NIH)MRE11
Genomic and cartography
GoldenPath hg19 (UCSC)MRE11  -     chr11:94150471-94227074 -  11q21   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)MRE11  -     11q21   [Description]    (hg38-Dec_2013)
EnsemblMRE11 - 11q21 [CytoView hg19]  MRE11 - 11q21 [CytoView hg38]
Mapping of homologs : NCBIMRE11 [Mapview hg19]  MRE11 [Mapview hg38]
OMIM600814   604391   
Gene and transcription
Genbank (Entrez)-
RefSeq transcript (Entrez)NM_001330347 NM_005590 NM_005591
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)MRE11
Cluster EST : UnigeneHs.192649 [ NCBI ]
CGAP (NCI)Hs.192649
Alternative Splicing GalleryENSG00000020922
Gene ExpressionMRE11 [ NCBI-GEO ]   MRE11 [ EBI - ARRAY_EXPRESS ]   MRE11 [ SEEK ]   MRE11 [ MEM ]
Gene Expression Viewer (FireBrowse)MRE11 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
BioGPS (Tissue expression)4361
GTEX Portal (Tissue expression)MRE11
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)MRE11
DMDM Disease mutations4361
Blocks (Seattle)MRE11
Human Protein AtlasENSG00000020922
HPRD02889
IPIIPI00940798   IPI00218853   IPI00029159   IPI01011534   IPI01012347   IPI01010110   IPI01009648   
Protein Interaction databases
FunCoupENSG00000020922
BioGRIDMRE11
STRING (EMBL)MRE11
ZODIACMRE11
Ontologies - Pathways
Huge Navigator MRE11 [HugePedia]
snp3D : Map Gene to Disease4361
BioCentury BCIQMRE11
ClinGenMRE11
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD4361
Chemical/Pharm GKB GenePA30934
Clinical trialMRE11
Miscellaneous
canSAR (ICR)MRE11 (select the gene name)
Probes
Litterature
PubMed256 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMRE11
EVEXMRE11
GoPubMedMRE11
iHOPMRE11
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Nov 18 20:09:43 CET 2016

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.